[Cefazedone in infectious diseases in gynecology. Clinical tests on efficacy and tolerance].
A clinical trial on efficacy and tolerance of Cefazedone, a new semisynthetic Cephalosporine-derivate, was carried out in a gynaecological clinic on 75 patients. In 38 of these cases, besides the gynaecological affection, urinary tract infections were determined microbiologically (E. coli, P. mirabilis, klebsiella or enterococci). Inflammation of the lower abdominal area was established in the remaining 37 patients (adnexitis, pelvic peritonitis, endometritis, salpingitis). The average duration of treatment was 10 to 11 days. Cefazedone was injected intravenously twice a day, the daily dose was 2 to 4 g. The clinical assessment of the treatment was very good in 28 cases, good in 43 cases, moderate in 3 patients and poor in 1 case. All initially identified pathogens were eliminated after treatment. A slight transitory diarrhea was observed in 5 cases. There were no further side-effects. The values of gamma-GT, serum-creatinin, hemoglobin and erythrozytes were controlled before and after medication and showed no detremental effect of the drug. The local tolerance of Cefazedone was good in more than 90% of the cases treated.
D000328:Adult; D002511:Cephalosporins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004361:Drug Tolerance; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D010538:Peritonitis / Q000188:drug therapy; D012488:Salpingitis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy; D014556:Urine / Q000382:microbiology
D002511:Cephalosporins
Cefazedon bei infektiösen Erkrankungen in der Frauenheilkunde Klinische Prüfung zur Wirksamkeit und Verträglichkeit.